This Article Full Text Full Text (PDF) All Versions of this Article: 50/4/792    most recent HYPERTENSIONAHA.107.095117v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Rivera, P. Articles by Jalil, J. E. Search for Related Content PubMed PubMed Citation Articles by Rivera, P. Articles by Jalil, J. E. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Nucleotide Protein UniGene Compound via MeSH Substance via MeSH Related Collections Remodeling Mechanism of atherosclerosis/growth factors ACE/Angiotension receptors Animal models of human disease Cell biology/structural biology Gene expression Smooth muscle proliferation and differentiation

(Hypertension. 2007;50:792.)
© 2007 American Heart Association, Inc.

XVIIth Scientific Meeting of the Inter-American Society of Hypertension

Rho Kinase Activation and Gene Expression Related to Vascular Remodeling in Normotensive Rats With High Angiotensin I–Converting Enzyme Levels

From the Department of Cardiovascular Diseases (P.R., M.P.O., J.E.J.), Medical School, P. Universidad Católica de Chile, Santiago, Chile; and the Department of Biochemistry and Molecular Biology (S.L.), Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, Santiago, Chile.

Correspondence to Jorge E. Jalil, P. Universidad Católica de Chile, Departamento de Enfermedades Cardiovasculares, Lira 85 Piso 2, Santiago, Chile. E-mail jjalil{at}med.puc.cl

The RhoA/Rho kinase (ROCK) pathway is a new mechanism of remodeling and vasoconstriction. Few data are available regarding ROCK activation when angiotensin I–converting enzyme is high and blood pressure is normal. We hypothesized that ROCK is activated in the vascular wall in normotensive rats with genetically high angiotensin I–converting enzyme levels, and it causes increased vascular expression of genes promoting vascular remodeling and also oxidative stress. Aortic ROCK activation, mRNA and protein levels (of monocyte chemoattractant protein-1, transforming growth factor [TGF]-ß₁, and plasminogen activator inhibitor-1 [PAI-1]), NADPH oxidase activity, and O₂^·– production were measured in normotensive rats with genetically high (Brown Norway [BN]) and low (Lewis) angiotensin-I–converting enzyme levels and in BN rats treated with the ROCK antagonist fasudil (100 mg/kg per day) for 7 days. ROCK activation was 12-fold higher in BN versus Lewis rats (P<0.05) and was reduced with fasudil by 100% (P<0.05). Aortic TGF-ß1, PAI-1, and monocyte chemoattractant protein-1 mRNA levels were higher in BN versus Lewis rats by 300%, 180%, and 1000%, respectively (P<0.05). Aortic TGF-ß1, PAI-1, and monocyte chemoattractant protein-1 protein levels were higher in BN versus Lewis rats (P<0,05). Fasudil reduced TGF-ß1 and PAI-1 mRNA and TGF-ß1, PAI-1, and monocyte chemoattractant protein-1 protein aortic levels to those observed in Lewis rats. Aortic reduced nicotinamide-adenine dinucleotide phosphate oxidase activity and ^.O₂^– production were increased by 88% and 300%, respectively, in BN rats (P<0.05) and normalized by fasudil. In conclusion, ROCK is significantly activated in the aortic wall in normotensive rats with genetically high angiotensin-I–converting enzyme and angiotensin II, and it causes activation of genes that promote vascular remodeling and also increases vascular oxidative stress.

Key Words: Rho kinase • angiotensin-converting enzyme • angiotensin • remodeling • fasudil • NADPH • hypertension